SG10201709090UA - Sobetirome in the treatment of myelination diseases - Google Patents
Sobetirome in the treatment of myelination diseasesInfo
- Publication number
- SG10201709090UA SG10201709090UA SG10201709090UA SG10201709090UA SG10201709090UA SG 10201709090U A SG10201709090U A SG 10201709090UA SG 10201709090U A SG10201709090U A SG 10201709090UA SG 10201709090U A SG10201709090U A SG 10201709090UA SG 10201709090U A SG10201709090U A SG 10201709090UA
- Authority
- SG
- Singapore
- Prior art keywords
- sobetirome
- treatment
- myelination diseases
- myelination
- diseases
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Gynecology & Obstetrics (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361819467P | 2013-05-03 | 2013-05-03 | |
| PCT/US2013/053640 WO2014178892A1 (en) | 2013-05-03 | 2013-08-05 | Use of sobetirome in the treatment of x-linked adrenolenoleukodystrophy |
| PCT/US2014/014943 WO2014178931A1 (en) | 2013-05-03 | 2014-02-05 | Sobetirome in the treatment of myelination diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201709090UA true SG10201709090UA (en) | 2017-12-28 |
Family
ID=51843844
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201709090UA SG10201709090UA (en) | 2013-05-03 | 2014-02-05 | Sobetirome in the treatment of myelination diseases |
| SG11201509012QA SG11201509012QA (en) | 2013-05-03 | 2014-02-05 | Sobetirome in the treatment of myelination diseases |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201509012QA SG11201509012QA (en) | 2013-05-03 | 2014-02-05 | Sobetirome in the treatment of myelination diseases |
Country Status (12)
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016517883A (ja) | 2013-05-03 | 2016-06-20 | オレゴン ヘルス アンド サイエンス ユニバーシティー | Ｘ連鎖副腎白質ジストロフィーの処置におけるソベチロムの使用 |
| WO2015168347A1 (en) | 2014-04-30 | 2015-11-05 | The Johns Hopkins University | Dendrimer compositions and their use in treatment of diseases of the eye |
| CN115350285A (zh) | 2014-08-13 | 2022-11-18 | 约翰霍普金斯大学 | 树枝状聚合物到脑肿瘤的选择性传递 |
| CA3003589C (en) * | 2015-10-29 | 2021-12-07 | The Johns Hopkins University | Dendrimer compositions and methods for treatment of peroxisomal disorders and leukodystrophies |
| ES2992773T3 (en) | 2016-04-22 | 2024-12-18 | Viking Therapeutics Inc | Use of thyroid beta-agonists |
| BR112018071559B1 (pt) * | 2016-04-22 | 2024-02-06 | Viking Therapeutics, Inc | Uso de um agonista de receptor beta de hormônios da tireoide para o tratamento de adrenoleucodistrofia ligada ao x |
| PL3457851T3 (pl) * | 2016-05-18 | 2022-03-14 | Oregon Health & Science University | Pochodne sobetiromu |
| KR102537274B1 (ko) * | 2016-08-12 | 2023-05-25 | 오레곤 헬스 앤드 사이언스 유니버시티 | 아마이드 화합물, 이의 약학 조성물 및 이들을 이용하는 방법 |
| WO2018183940A1 (en) * | 2017-03-31 | 2018-10-04 | Neurovia, Inc. | Methods and compositions for treating niemann-pick disease |
| WO2018201007A2 (en) | 2017-04-27 | 2018-11-01 | The Johns Hopkins University | Dendrimer compositions for use in angiography |
| WO2018208707A1 (en) * | 2017-05-08 | 2018-11-15 | Neurovia, Inc. | Methods and compositions for treating demyelinating diseases |
| US10780069B2 (en) * | 2017-05-18 | 2020-09-22 | University of Pittsburgh—of the Commonwealth System of Higher Education | Use of GC-1 in transplant related population |
| WO2019005816A1 (en) | 2017-06-29 | 2019-01-03 | Yale University | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING FIBROUS PULMONARY DISEASES |
| JP7109794B2 (ja) | 2017-07-18 | 2022-08-02 | 慶應義塾 | Ｔｈ１細胞誘導性細菌に対する抗菌組成物 |
| CA3082121C (en) | 2017-11-10 | 2023-01-24 | The Johns Hopkins University | Dendrimer delivery system and methods of use thereof |
| US11827596B2 (en) | 2018-12-12 | 2023-11-28 | Autobahn Therapeutics, Inc. | Thyromimetics |
| AU2020232205A1 (en) | 2019-03-01 | 2021-10-21 | Autobahn Therapeutics, Inc. | Novel thyromimetics |
| AU2020391467A1 (en) | 2019-11-29 | 2022-06-23 | Autobahn Therapeutics, Inc. | Novel thyromimetics |
| US11612660B2 (en) | 2019-12-04 | 2023-03-28 | Ashvattha Therapeutics, Inc. | Dendrimer compositions and methods for drug delivery to the eye |
| CN111116684B (zh) * | 2019-12-31 | 2020-09-25 | 厦门甘宝利生物医药有限公司 | 一种具有甲状腺激素受体激动剂特性的肝靶向化合物及其药物组合物 |
| CN115569233B (zh) * | 2022-10-17 | 2023-07-14 | 湖南大学 | 既能吸光又能与自由基反应的高效光抑制剂的制备方法 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3815221C2 (de) | 1988-05-04 | 1995-06-29 | Gradinger F Hermes Pharma | Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen |
| WO1997021993A2 (en) | 1995-12-13 | 1997-06-19 | The Regents Of The University Of California | Nuclear receptor ligands and ligand binding domains |
| CA2260992C (en) | 1996-08-20 | 2004-03-09 | The Regents Of The University Of California | Eye treatments using synthetic thyroid hormone compositions |
| US5883294A (en) | 1997-06-18 | 1999-03-16 | The Regeants Of The University Of California | Selective thyroid hormone analogs |
| DK1089968T3 (da) | 1998-06-30 | 2005-08-22 | Univ California | Thyroideahormonanaloger og fremgangsmåder til deres fremstilling |
| US7560433B2 (en) | 2001-12-21 | 2009-07-14 | Biotempt B.V. | Treatment of multiple sclerosis (MS) |
| US7302347B2 (en) | 2002-12-10 | 2007-11-27 | The Regents Of The University Of California | Method for creating specific, high affinity nuclear receptor pharmaceuticals |
| US8071134B2 (en) * | 2003-09-15 | 2011-12-06 | Ordway Research Institute, Inc. | Thyroid hormone analogs and methods of use |
| CN1878545A (zh) * | 2003-09-15 | 2006-12-13 | 奥德威研究院 | 甲状腺激素类似物及其使用方法 |
| WO2006031922A2 (en) * | 2004-09-15 | 2006-03-23 | Ordway Research Institute | Thyroid hormone analogs for promoting angiogenesis |
| WO2006012015A2 (en) | 2004-06-29 | 2006-02-02 | Oregon Health And Science University | Methods and compositions for nerve regeneration |
| WO2006105205A1 (en) | 2005-03-29 | 2006-10-05 | University Of Kentucky Research Foundation | Sublingual spray for the treatment of pain |
| US8252329B2 (en) | 2007-01-05 | 2012-08-28 | Acelrx Pharmaceuticals, Inc. | Bioadhesive drug formulations for oral transmucosal delivery |
| BRPI0718283A2 (pt) | 2006-10-20 | 2013-11-12 | Biogen Idec Inc | Tratamento de distúrbios desmielinizantes |
| CN101610774B (zh) * | 2006-11-03 | 2012-04-04 | 萨斯喀彻温大学 | 治疗脱髓鞘疾病的方法 |
| FI20075245A0 (fi) * | 2007-04-11 | 2007-04-11 | Markku Ahotupa | Menetelmä oksidatiivisen metabolian arvioimiseksi |
| PL2187882T3 (pl) | 2007-07-11 | 2013-05-31 | Medicinova Inc | Leczenie postępującej choroby neurodegeneracyjnej ibudilastem |
| EP2242745A1 (de) * | 2008-02-07 | 2010-10-27 | Sanofi-Aventis | Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| CN102014957B (zh) * | 2008-04-21 | 2014-12-10 | 奥德纳米有限公司 | 用于治疗耳部疾病和病况的耳用调配物 |
| US20120058962A1 (en) | 2009-05-20 | 2012-03-08 | Lingual Conseqna Pty Ltd. | Buccal and/or sublingual therapeutic formulation |
| TW201221505A (en) * | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| JP5786195B2 (ja) | 2010-12-16 | 2015-09-30 | シナプサス セラピューティクス，インコーポレーテッド | 舌下フィルム |
| BR112015009313B1 (pt) * | 2012-10-25 | 2021-03-23 | Volvo Truck Corporation | Sistema de freio pneumático controlado eletronicamente para um veículo automotivo, veículo automotivo equipado com um tal sistema e método para controle de um tal sistema |
| JP2016517883A (ja) | 2013-05-03 | 2016-06-20 | オレゴン ヘルス アンド サイエンス ユニバーシティー | Ｘ連鎖副腎白質ジストロフィーの処置におけるソベチロムの使用 |
-
2013
- 2013-08-05 JP JP2016511718A patent/JP2016517883A/ja not_active Withdrawn
- 2013-08-05 WO PCT/US2013/053640 patent/WO2014178892A1/en active Application Filing
-
2014
- 2014-02-05 ES ES14791718T patent/ES2745532T3/es active Active
- 2014-02-05 SG SG10201709090UA patent/SG10201709090UA/en unknown
- 2014-02-05 WO PCT/US2014/014943 patent/WO2014178931A1/en active Application Filing
- 2014-02-05 CA CA2911309A patent/CA2911309A1/en not_active Abandoned
- 2014-02-05 JP JP2016511726A patent/JP6360552B6/ja active Active
- 2014-02-05 EP EP14791718.1A patent/EP2991670B8/en active Active
- 2014-02-05 AU AU2014260468A patent/AU2014260468A1/en not_active Abandoned
- 2014-02-05 US US14/888,577 patent/US10226438B2/en active Active
- 2014-02-05 MX MX2015015228A patent/MX379043B/es unknown
- 2014-02-05 CN CN201480038129.XA patent/CN105431163A/zh active Pending
- 2014-02-05 BR BR112015027682A patent/BR112015027682A2/pt not_active IP Right Cessation
- 2014-02-05 SG SG11201509012QA patent/SG11201509012QA/en unknown
- 2014-02-05 RU RU2015151216A patent/RU2015151216A/ru not_active Application Discontinuation
-
2015
- 2015-10-30 MX MX2021000538A patent/MX2021000538A/es unknown
-
2018
- 2018-06-22 JP JP2018118891A patent/JP2018141024A/ja active Pending
- 2018-07-23 JP JP2018137754A patent/JP2018162321A/ja active Pending
-
2019
- 2019-02-13 US US16/275,117 patent/US20190175531A1/en not_active Abandoned
-
2020
- 2020-07-07 US US16/922,852 patent/US11510887B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2991670B8 (en) | 2019-09-11 |
| EP2991670A4 (en) | 2017-01-18 |
| WO2014178931A8 (en) | 2015-11-26 |
| MX2015015228A (es) | 2016-10-03 |
| WO2014178931A1 (en) | 2014-11-06 |
| HK1222552A1 (en) | 2017-07-07 |
| US11510887B2 (en) | 2022-11-29 |
| RU2015151216A (ru) | 2017-06-08 |
| JP2016517883A (ja) | 2016-06-20 |
| JP2016517884A (ja) | 2016-06-20 |
| JP6360552B2 (ja) | 2018-07-18 |
| MX379043B (es) | 2025-03-10 |
| JP2018141024A (ja) | 2018-09-13 |
| CN105431163A (zh) | 2016-03-23 |
| JP2018162321A (ja) | 2018-10-18 |
| WO2014178892A1 (en) | 2014-11-06 |
| US10226438B2 (en) | 2019-03-12 |
| WO2014178892A8 (en) | 2015-12-17 |
| US20190175531A1 (en) | 2019-06-13 |
| MX2021000538A (es) | 2021-04-28 |
| CA2911309A1 (en) | 2014-11-06 |
| BR112015027682A2 (pt) | 2017-08-29 |
| US20160081955A1 (en) | 2016-03-24 |
| US20200405669A1 (en) | 2020-12-31 |
| AU2014260468A1 (en) | 2015-11-19 |
| ES2745532T3 (es) | 2020-03-02 |
| SG11201509012QA (en) | 2015-11-27 |
| EP2991670B1 (en) | 2019-07-03 |
| JP6360552B6 (ja) | 2018-08-15 |
| EP2991670A1 (en) | 2016-03-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201509012QA (en) | Sobetirome in the treatment of myelination diseases | |
| IL286759A (en) | Therapeutic methods and preparations | |
| GB201320729D0 (en) | Therapeutic compounds and their use | |
| GB201321743D0 (en) | Therapeutic agents | |
| GB201321738D0 (en) | Therapeutic Agents | |
| GB201321736D0 (en) | Therapeutic agents | |
| GB2516814B (en) | Use of phytocannabinoids for increasing radiosensitivity in the treatment of cancer | |
| GB201321729D0 (en) | Therapeutic agents | |
| GB201321728D0 (en) | Therapeutic agents | |
| GB201321733D0 (en) | Therapeutic agents | |
| IL239368A0 (en) | Sparing–ppar thiazolidinediones and combinations for the treatment of neurodegenerative diseases of the nervous system | |
| GB201321739D0 (en) | Therapeutic agents | |
| GB201321730D0 (en) | Therapeutic agents | |
| GB201321741D0 (en) | Therapeutic agents | |
| GB201321740D0 (en) | Therapeutic agents | |
| GB201321734D0 (en) | Therapeutic Agents | |
| GB201321732D0 (en) | Therapeutic agents | |
| GB201321737D0 (en) | Therapeutic Agents | |
| GB201321744D0 (en) | Therapeutic agents | |
| GB201321742D0 (en) | Therapeutic agents | |
| GB201321735D0 (en) | Therapeutic Agents | |
| GB201311361D0 (en) | Compounds and their therapeutic use | |
| GB201321731D0 (en) | Therapeutic agents | |
| GB201308440D0 (en) | Therapeutic | |
| ZA201500547B (en) | Alpha-1-microglobulin for use in the treatment of mitochondria-related diseases |